Auxeris Therapeutics Inc is categorized under Commercial Medical Research in Saint Louis, MO and active since 2002.
Auxeris Therapeutics Inc was established in 2002, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Commercial Medical Research business, which does work in the B2B market, and is classified as a Commercial Medical Research, under code number 541712 by the NAICS.
If you are seeking more information, feel free to contact Laurent Fischer at the company’s single location by writing to 4041 Forest Park Avenue, Saint Louis, Missouri MO 63108 or by phoning (314) 633-1880. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Auxeris Therapeutics Inc |
| Contact Person: | Laurent Fischer |
| Address: | 4041 Forest Park Avenue, Saint Louis, Missouri 63108 |
| Phone Number: | (314) 633-1880 |
| Annual Revenue (USD): | $500.000 to $999.999 |
| Founded: | 2002 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Medical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541712 |
| Share This Business: |
Auxeris Therapeutics Inc was started in 2002 to provide professional Commercial Medical Research under the SIC code 8731 and NAICS code 541712. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.
Feel free to contact Laurent Fischer for inquiries that concern Auxeris Therapeutics Inc by calling the company number (314) 633-1880, as your correspondence is most welcome. Additionally, the physical location of the single location of Auxeris Therapeutics Inc can be found at the coordinates 38.635808,-90.245999 as well as the street address 4041 Forest Park Avenue in Saint Louis, Missouri 63108.
For its online presence, you may visit Auxeris Therapeutics Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.